Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial
Open Access
- 23 April 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (3) , 1476-1481
Abstract
We explored the efficacy and safety of brentuximab vedotin, a chimeric anti-CD30 antibody drug conjugate, in patients with severe active diffuse cutaneous systemic sclerosis (dcSSc). This phase II proof-of-concept, single centre, open-label, single arm, investigator-initiated trial included patients ≥18 years, with dcSSc, modified Rodnan skin score (mRSS) ≥15 with P = 0.001), meeting the primary end point in the intention to treat analysis (7/11 had a decrease in mRSS ≥8). The % forced vital capacity increased by 7.8% (12.5). The Composite Response Index in dcSSc (CRISS) suggested a beneficial treatment effect (86% ≥0.6). Most adverse events were mild. No SAEs were attributed to brentuximab vedotin. In dcSSc, brentuximab vedotin improved skin and FVC without safety concerns. A placebo-controlled trial is warranted to corroborate these initial findings. ClinicalTrials.gov, http://clinicaltrials.gov, NCT03198689.Keywords
Funding Information
- Seagen
- AstraZeneca
This publication has 25 references indexed in Scilit:
- Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic SclerosisArthritis & Rheumatology, 2020
- Treatment Algorithms for Systemic Sclerosis According to ExpertsArthritis & Rheumatology, 2018
- Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-AnalysisTransplantation and Cellular Therapy, 2018
- The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisArthritis & Rheumatology, 2016
- Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic SclerosisJAMA, 2014
- Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six‐month, randomized, double‐blind, placebo‐controlled, proof‐of‐concept pilot study at a single centerArthritis & Rheumatism, 2011
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001
- Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trialArthritis & Rheumatism, 2000
- The value of the health assessment questionnaire and special patient‐generated scales to demonstrate change in systemic sclerosis patients over timeArthritis & Rheumatism, 1997
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980